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BACKGROUND/OBJECTIVES: Ophthalmic disorders cause 8% of hospital clinic attendances, the highest of any specialty. The
fundamental need for a distance visual acuity (VA) measurement constrains remote consultation. A web-application, DigiVis,
facilitates self-assessment of VA using two internet-connected devices. This prospective validation study aimed to establish its
accuracy, reliability, usability and acceptability.
SUBJECTS/METHODS: In total, 120 patients aged 5–87 years (median= 27) self-tested their vision twice using DigiVis in addition to
their standard clinical assessment. Eyes with VA worse than +0.80 logMAR were excluded. Accuracy and test-retest (TRT) variability
were compared using Bland–Altman analysis and intraclass correlation coefficients (ICC). Patient feedback was analysed.
RESULTS: Bias between VA tests was insignificant at −0.001 (95% CI −0.017 to 0.015) logMAR. The upper limit of agreement (LOA)
was 0.173 (95% CI 0.146 to 0.201) and the lower LOA −0.175 (95% CI −0.202 to −0.147) logMAR. The ICC was 0.818 (95% CI 0.748 to
0.869). DigiVis TRT mean bias was similarly insignificant, at 0.001 (95% CI −0.011 to 0.013) logMAR, the upper LOA was 0.124 (95% CI
0.103 to 0.144) and the lower LOA −0.121 (95% CI −0.142 to −0.101) logMAR. The ICC was 0.922 (95% CI 0.887 to 0.946). 95% of
subjects were willing to use DigiVis to monitor vision at home.
CONCLUSIONS: Self-tested distance VA using DigiVis is accurate, reliable and well accepted by patients. The app has potential to
facilitate home monitoring, triage and remote consultation but widescale implementation will require integration with NHS
databases and secure patient data storage.
Eye; https://doi.org/10.1038/s41433-021-01760-2
INTRODUCTION
Corrected distance visual acuity (VA) is a fundamental measure of
visual resolution and is assessed before every ophthalmic,
optometric, and orthoptic examination to inform clinical decision
making. The standard method for VA assessment requires a
trained observer to assess the smallest optotype that a patient can
identify on an illuminated chart displayed at a set viewing
distance. In specialist practice, the Snellen chart has largely been
replaced by the Early Treatment of Diabetic Retinopathy Study
(ETDRS) chart based on the logarithm of the Minimal Angle of
Resolution (logMAR), conferring a more accurate estimation of VA
than the Snellen chart due to its greater number of letter rows and
the even crowding of letters on each line [1]. Variation in
concentration, chart properties, viewing distance and observer
bias are known to cause substantial fluctuations in test repeat-
ability [2].
Ophthalmology clinics are the busiest in acute hospital trusts
with nearly eight million attendances per year in the NHS; a high
proportion are follow-up appointments for vision monitoring. This
specialty workload is predicted to increase in coming years [3],
and the NHS Long Term Plan requires a third of appointments to
become virtual to increase clinic capacity [4]. COVID-19 has
generated even greater urgency for change, with infection risk
minimised by reducing clinic footfall and increasing the efficiency
of emergency triage [5]. These targets can only be reached if
patients can accurately self-test and monitor their visual function
at home. Although many apps have been marketed to enable self-
testing of vision, the majority test near vision only and have not
been validated or CE marked. There remains an urgent require-
ment for a validated, accurate, and reliable method of self-testing
distance VA [6–8].
DigiVis (www.digivis.org) is a recently developed CE marked
web-application which facilitates self-testing of VA at home. It
requires two internet-connected devices: one device (tablet or
laptop) acts as a distant letter display screen and is paired with a
handheld device (smartphone or tablet), which serves as
the patient input device. An automated psychophysical staircase
algorithm automatically changes the letter size on the distance
tablet, based on patient input, enabling threshold VA to
be calculated and stated in a range of different formats (Snellen
notation, logMAR and cumulative number of letters). Consistent
crowding of optotypes potentially gives DigiVis the reliability
benefits of the standard ETDRS chart whilst its automated
staircase and reversal algorithm removes observer bias and may
improve precision.
This study aimed to assess the accuracy and reliability of DigiVis
VA self-testing and to quantify its usability and acceptability in
patients attending a hospital ophthalmology clinic appointment.
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The DigiVis test can be undertaken on a range of devices. A tablet, laptop
or desktop screen displays the distance letter test chart and a smartphone
or tablet is used as the patient input device. An animated instruction video
in the application demonstrates the calibration steps. The distant test chart
screen resolution calculation is undertaken by dragging virtual callipers on
the distant test chart to match the size of a credit or store card held up
against it. Patients can then choose to measure their 2 m viewing distance
either with a tape measure or by using a novel automated distance
calibration system within the application. This system asks patients to
focus the second device’s camera on a graphic presented on the larger
device screen, first at 30 cm (the length of an A4 sheet of paper) then
approximately 2 m distance. The application compensates for discrepancy
from 2m by adjusting optotype sizing to adapt for distance viewing
between 1.5 and 2.5 m if the patient is unable to measure distance
manually. The test will not start if the viewing distance lies outside the
1.5–2.5 m range.
Sloan letter optotypes are presented on the larger screen with crowding
consistent with the letter size. The letter display is randomised and an
arrow indicates the letter which the patient is required to identify (Fig. 1a).
If able to recognise the letter, the patient selects the matching optotype
out of a group of five displayed on their handheld device (four of which are
randomised), or a ‘Not Sure’ option (Fig. 1b). For children under 10 years
the test runs similarly, but features animations appearing upon
letter selection, encouraging participation by gamifying the test: “collect-
ing animals by matching letters”. Optotype size follows a modified
García–Pérez psychophysical staircase with three reversal points, facilitat-
ing calculation of VA according to the smallest identifiable letter size [9]. A
lower limit of 0.00 logMAR was set as a minimum threshold in
this investigation to reduce testing time. The duration of the test may
range from 30 s to 2min, depending on the consistency of subjects’
responses.
Participants
This was a prospective validation study comparing DigiVis VA self-testing
to standard clinical testing. All procedures adhered to the tenets of the
Declaration of Helsinki for research involving human subjects and the
protocol was reviewed by the Health Research Authority and Health and
Care Research Wales Ethics Committee.
Over a two-month period during the COVID-19 lockdown, research
administrators posted study participation invitations and information
leaflets to all patients due to attend a follow-up face to face eye clinic
appointment. Inclusion criteria were as follows: age over four years, VA of
+0.8 logMAR (6/38 Snellen) or better in each eye and no documentation of
cognitive disability or requirement for interpreting services in the
electronic patient records. The invitation letter encouraged patients who
had access to two internet connected digital devices and wanted to
participate to contact a clinician researcher. The clinician researcher
phoned the patient to explain the study, take verbal consent and give
password access to the DigiVis test.
Testing
Patients were requested to undertake DigiVis testing twice before their
clinic appointment, write down their VA scores and complete a usability
and acceptance questionnaire to bring to the clinic with them. They were
asked to contact the clinician researcher if they needed technical support
during the tests. Written informed consent was given at the time of the
hospital attendance.
Patients who had agreed to participate but forgotten to undertake the
testing at home were re-invited to participate at the time of their clinic
attendance and, after giving written informed consent, undertook DigiVis
testing in a side-room at clinic. Patients were asked to watch the
instruction video on the website and set up the system themselves, but
medical students were on hand to offer technical support if required.
Those using DigiVis at home used their own internet-connected devices.
Those using DigiVis in clinic used their own handheld device with a
department computer as the test chart. Background and device lighting
were not controlled, and patients could modify their environment as
desired.
At participants’ appointments, a standard, age-appropriate clinical
assessment of VA was undertaken by nurse, optometrist, or orthoptist
(blinded to previous DigiVis acuity measurement) and recorded. Patients
were asked to hand in a usability and acceptance questionnaire alongside
their consent form for DigiVis during their clinic visit. Paediatric patients
completed a simpler feedback questionnaire and provided a form of
written informed assent; parents or guardians completed the standard
questionnaire and provided written informed consent.
Analysis
Data from right eyes only were analysed, to avoid co-dependence.
Agreement between DigiVis and clinical VA measurements, as well as test-
retest (TRT) agreement was evaluated with Bland-Altman plots, looking
specifically at 95% limits of agreement (LOA) and mean bias, and with
mixed effects-model two-way intraclass correlation coefficients (ICC).
Where the standard assessment was undertaken using a Snellen chart,
VA was converted to logMAR in Microsoft Excel [10] (v16.45, Microsoft
Corporation, Redmond, Washington, United States). Analysis and data
visualisation were conducted in R (v3.6.1, R Foundation for Statistical
Computing, Vienna, Austria) and Affinity Designer (v1.8.6, Pantone LLC,
Carlstadt, New Jersey, United States).
RESULTS
Participant demographics
in total, 511 invitations to participate in the study were posted to
eligible patients by the research team. The right eyes of the 120
patients who responded (23%) were tested using the DigiVis app
and by standard, age-appropriate clinical assessment by a trained
healthcare worker. Of these patients, 105 (88%) completed two
DigiVis tests, enabling TRT agreement to be appraised. Subject VA
based on standard clinical testing ranged from less than 0–0.8
Fig. 1 Screenshots from the DigiVis web-app during testing, from the larger screen (a) and handheld device (b). Patients select which
optotype is indicated by arrows on the larger screen, from a range of choices on the handheld device.















logMAR (mean 0.07 logMAR). Patient ages ranged from 5–87
years, distributing as depicted in Fig. 2. There were 44 (37%) 5–10
year olds (instructed to undertake the children’s version of the
DigiVis test), 32 (27%) between 55 and 75, and seven (6%) over 75.
36 (30%) patients undertook the DigiVis test in a side-room at
clinic prior to their appointment; 84 (70%) undertook self-testing
at home.
Accuracy and reliability of visual acuity measurements
To facilitate Bland-Altman analysis, differences are plotted
against mean values, for the first DigiVis VA and clinical
measurement, as well as for repeated DigiVis VA measurements
(Fig. 3). Bland-Altman bias and limits of agreement, as well as ICC
and associated statistics, are stated in Table 1. In both cases, the
mean bias was not statistically significantly different from 0.00
logMAR as indicated by the inclusion of the x-axis within the
confidence intervals. LOA lie on average at ±0.174 logMAR when
comparing DigiVis and clinical measurements, and at ±0.123
logMAR when comparing repeated DigiVis measurements. In both
comparisons, there was no significant correlation (Pearson’s
correlation coefficient, p > 0.05) between differences in VA and
means of VA, indicating consistent performance across the tested
range.
ICCs indicated good (over 0.75) and excellent (over 0.90)
agreement when comparing DigiVis and clinical measurements,
and repeated DigiVis measurements, respectively. Similarly strong
agreement was observed in left eyes.
Patient feedback
Feedback was very positive: 49/53 (92%) children, 49/50 (98%)
parents, and 57/61 (93%) adult patients rated DigiVis as’good’
or’excellent’, and 95% of patients and parents said they would be
willing to use DigiVis to monitor vision at home. Patients were
especially enthusiastic about the website’s detailed instructions,
and option to potentially conduct a home test rather than attend
a clinic. Of individuals that provided negative feedback, the most
common issues were a lack of suitable devices to conduct the test
at home, and concern that results may not be accurate.
DISCUSSION
Conventional chart-based assessment of VA has reported TRT LOA
of ±0.15 logMAR [11], close to a theoretical maximum of ±0.14
logMAR determined in strictly controlled conditions [2]. Peek
Acuity, a distance VA testing app, has reported LOA between app
and clinical measurements of ±0.444 logMAR and TRT LOA of
Fig. 2 Histogram and overlain density plot illustrating the distribution of age in the participating population.
Fig. 3 Bland-Altman plots comparing DigiVis and clinical measurements (right), and repeated DigiVis measurements (left). The bias and
95% LOA are indicated by dashed lines, whilst shaded 95% confidence intervals for each are bounded by dotted lines.
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±0.414 logMAR [12]. The LOA between the Kays pictures iSight
app and clinical measurements is reported as ±0.125–0.208
logMAR [13]. COMPlog, a distance VA test requiring a specifically
sized computer monitor and trained observer, recorded TRT LOA
at ±0.10–0.12 logMAR [14], and ICC of 0.964 when comparing face
to face with remote testing [15]. Other smartphone-based VA
testing apps have reported LOAs of ±0.198 logMAR [16] and
±0.10-0.30 logMAR under clinical supervision [17]. Together, these
data provide a priori standards by which DigiVis can be evaluated.
In this study, DigiVis self-test VA assessment had minimal bias,
LOAs of ±0.174 when compared to standard clinical testing, and
TRT LOAs of ±0.123 logMAR, without clinical supervision,
favourable compared to other apps, and even clinical testing.
High ICC values reinforce evidence of its accuracy and reliability.
The narrowness of confidence intervals for calculated statistics
suggests that the sampled population was sufficiently large to
provide robust results. Advantages of DigiVis include the
automated calculation and calibration of distance between patient
and screen (overcoming the known issue of observer distance
determination affecting test results), as well as the use of crowded
letter optotypes which enable direct comparison to previous
standard clinical testing. The forced-choice nature of the DigiVis
test and the absence of observer bias are likely to result in
improved test reliability relative to clinical assessment [18].
There were several limitations of this study. The number of
participants was smaller than the number invited; a proportion of
those that did not participate may not have had digital access to
the test. Although 70% of DigiVis testing was conducted
successfully at home on patients’ own devices, 30% undertook
the test at clinic, which may have made gaining access and setting
up the test easier. The age distribution of the sampled population
was weighted towards the under-10 and 55-75 age groups. The
relatively lower proportion of elderly participants likely reflects the
pattern of attendance at eye clinics during the COVID-19
lockdown period. Standard clinical testing was carried out using
a variety of standard charts: Snellen, ETDRS and children’s logMAR
flip charts. This reflects real-world variation in ophthalmology
clinics but may have reduced the reliability of clinical measure-
ments. Another limitation of this analysis was the exclusion of
patients with VA worse than +0.8 logMAR, a decision made due to
the presumed difficulties these individuals may have in accessing
the test. Few participants in this study had vision worse than 0.5
logMAR–further investigation in patients with poorer visual
acuities is required to verify the app’s potential in this population.
Finally, although DigiVis test-retest agreement may suggest
superior reliability to clinical assessment, its apparent consistency
may have been inflated by participants repeating the test in quick
succession, in the same testing environment and on the same
devices.
DigiVis represents a validated means of obtaining accurate and
reliable visual acuity data without supervision. Particular benefits
of the application include: (1) the nature of a distance VA test
directly comparable to chart-based assessment; (2) complete
automation of the test, not requiring clinician input; (3) CE
marking and validated accuracy and reliability, and (4) measure-
ment of viewing distance with compensatory size-adjustment of
optotypes. This could prove useful in enabling patients to self-
monitor and report their VA, augmenting remote consultations.
Asynchronous (maximising patient autonomy) or synchronous
(facilitating clinician input via screen-sharing) testing may be
utilised as required. For those shielding or self-isolating for COVID-
19, DigiVis VA assessment may enable a clinician and the patient
to balance the urgency of an in-person consultation with the risk
of hospital attendance. As a result of school closures, a year’s
cohort of children have missed school vision screening (700,000
children in the UK). DigiVis assessment at home may facilitate
catch-up vision screening, although further testing in 4 to 5-year-
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difficulty in accessing the test due to the unavailability of digital
devices, internet connection, or difficulties with the instructions
could undertake testing in local community centres or be guided
in its use through the screen-share functionality of video-
consulting software.
This clinical validation study indicates that DigiVis self-testing is
a viable alternative to standard clinical assessment of VA in
patients aged five years and older. Further studies are needed to
validate its use in the elderly, patients with VA worse than 0.5
logMAR, and vision screening in young children. The web-app has
the potential to support triage and remote consultations for
ophthalmology services and be used for VA testing in primary and
secondary care where a standard chart or suitable trained
examiner is not available, for instance, general practice, emer-
gency departments, and in-patient wards. Additional support or
alternative testing will still be necessary for patients with severe
visual impairment, cognitive impairment, or who struggle with
digital access. For selected patients, VA apps have the potential to
reduce the need for clinic attendance, and workload, but require
integration into patient pathways, clinician workflows, and
electronic patient records.
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